Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | GFER | P55789 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | HTR1D | P28221 | 2/20 | 0.59 |
| ▸ | HTR6 | P50406 | 2/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | HTR1E | P28566 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31498186 | 0.85 | KDM4E (0.59) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL5196745 | 0.85 | KDM4E (0.59) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL17452876 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL29391519 | 0.81 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL2597652 | 0.81 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL11488805 | 0.80 | HTR6 (0.58) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL11374190 | 0.79 | ALDH1A1 (0.78) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL11808162 | 0.79 | TUBB4A (0.62) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL5838270 | 0.79 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL14019351 | 0.79 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0502733-B1 | Air-activatable polymerisable compositions | LOCTITE IRELAND LTD (IE) | 1997-09-10 | — | — | EP | claimed |
| EP-0502733-A1 | Air-activatable polymerisable compositions | LOCTITE (IRELAND) Ltd. (IE) | 1992-09-09 | — | — | EP | claimed |
| EP-3233797-B1 | MAP4K4 (HGK) INHIBITORS | Sri int inc (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| EP-3169683-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen Ltd. (AU) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016187667-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016008011-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016008011-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| US-5683536-A | PEROXIDE-FREE AUTOOXIDIZABLE FREE RADICAL CATALYST | LOCTITE LTD. (IE) | 1997-11-04 | — | — | US | disclosed |
| EP-0502733-A1 | Air-activatable polymerisable compositions | LOCTITE (IRELAND) Ltd. (IE) | 1992-09-09 | — | — | EP | disclosed |
| US-4310634-A | 1-HYDRAZINO-2-HYDRAZONO ETHANE | TEXACO DEVELOPMENT CORP. (US) | 1982-01-12 | — | — | US | disclosed |
| US-4286072-A | 1-/DIALKYLHYDRAZONO/-2-HYDROXYETHANES; POLYURETHANE-POLYISOCYANURATE FOAMS | TEXACO DEVELOPMENT CORP. (US) | 1981-08-25 | — | — | US | disclosed |
| US-4251637-A | TO PREPARE A POLYMER CONTAINING RECURRING ISOCYANURATE AND URETHANE LINKAGES | TEXACO DEVELOPMENT CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | ALDH1A1 1080/4885MEN1 3325/4885KMT2A 2215/4885 |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | ALDH1A1 1176/4885MEN1 2944/4885KMT2A 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.